IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Inceptionr LLC

Inceptionr LLC lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 80.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,045 shares of the medical research company's stock after selling 4,343 shares during the quarter. Inceptionr LLC's holdings in IQVIA were worth $242,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. AdvisorNet Financial Inc lifted its stake in shares of IQVIA by 327.6% in the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company's stock valued at $29,000 after purchasing an additional 95 shares during the last quarter. BKM Wealth Management LLC purchased a new position in IQVIA during the fourth quarter worth $32,000. Activest Wealth Management bought a new position in IQVIA during the fourth quarter valued at $35,000. CVA Family Office LLC purchased a new stake in shares of IQVIA in the fourth quarter valued at $43,000. Finally, CoreFirst Bank & Trust bought a new stake in shares of IQVIA in the 3rd quarter worth about $44,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares of the company's stock, valued at approximately $199,610,278.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kevin C. Knightly sold 8,607 shares of the business's stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the sale, the insider now directly owns 5,251 shares in the company, valued at approximately $1,313,642.67. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

IQVIA Stock Down 1.6 %

Shares of NYSE IQV traded down $3.82 during mid-day trading on Friday, reaching $231.18. 715,158 shares of the company were exchanged, compared to its average volume of 958,819. The firm has a 50-day moving average of $239.90 and a 200 day moving average of $227.17. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. The stock has a market cap of $42.12 billion, a price-to-earnings ratio of 31.58, a P/E/G ratio of 2.34 and a beta of 1.52.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating analysts' consensus estimates of $2.82 by $0.02. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. The business had revenue of $3.87 billion for the quarter, compared to analysts' expectations of $3.80 billion. During the same period last year, the business earned $2.54 EPS. The company's revenue was up 3.5% compared to the same quarter last year. On average, research analysts expect that IQVIA Holdings Inc. will post 10.1 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on IQV. Leerink Partnrs reissued an "outperform" rating on shares of IQVIA in a research report on Monday, February 26th. SVB Leerink started coverage on IQVIA in a report on Monday, February 26th. They set an "outperform" rating and a $290.00 price objective for the company. Truist Financial decreased their target price on IQVIA from $297.00 to $292.00 and set a "buy" rating for the company in a research report on Friday, May 3rd. Barclays upped their price target on shares of IQVIA from $260.00 to $265.00 and gave the stock an "overweight" rating in a report on Thursday, February 15th. Finally, UBS Group lifted their price objective on shares of IQVIA from $240.00 to $300.00 and gave the company a "buy" rating in a report on Thursday, February 15th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $257.57.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.